CV risk lower with metformin in T2DM and reduced kidney function

CV risk lower with metformin in T2DM + reduced kidney function

(HealthDay)—Treatment with metformin versus sulfonylureas is associated with a reduced risk for major adverse cardiovascular events (MACE) among patients with type 2 diabetes and reduced kidney function, according to a study published online Sept. 19 in the Journal of the American Medical Association to coincide with the annual meeting of the European Association for the Study of Diabetes, held from Sept. 16 to 20 in Barcelona, Spain.

Christianne L. Roumie, M.D., M.P.H., from the Veteran Administration Tennessee Valley VA Health Care System Geriatric Research Education Clinical Center in Nashville, Tennessee, and colleagues conducted a retrospective cohort study of U.S. veterans to compare MACE among patients with diabetes and reduced . The weighted cohort included 24,679 users and 24,799 sulfonylurea users with a median estimated of 55.8 mL/min/1.73 m² and hemoglobin A1c of 6.6 percent.

The researchers identified 1,048 MACE outcomes among metformin users and 1,394 events among sulfonylurea users (23.0 and 29.2 per 1,000 person-years, respectively) during follow-up (1.0 and 1.2 years, respectively). For metformin versus a sulfonylurea, the cause-specific adjusted hazard ratio for MACE was 0.80, yielding an adjusted rate difference of 5.8 fewer events per 1,000 person-years for metformin versus sulfonylurea use.

"This study and the results add to the limited observational evidence for the beneficial association of metformin compared with sulfonylurea and cardiovascular outcomes among those who develop reduced kidney function," the authors write.

One author disclosed financial ties to the pharmaceutical industry.


Explore further

Sulfonylureas up cardio events versus metformin

More information: Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
More Information

Copyright © 2019 HealthDay. All rights reserved.

Citation: CV risk lower with metformin in T2DM and reduced kidney function (2019, September 19) retrieved 15 November 2019 from https://medicalxpress.com/news/2019-09-cv-metformin-t2dm-kidney-function.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments